B. Riley Securities lowered its price target on Skyworks Solutions, citing ongoing softness in the Android smartphone segment that is expected to weigh on near-term guidance, despite strength from Apple's iPhone cycle and diversification efforts.
Microsoft's free cash flow took a significant hit last quarter due to soaring capital expenditures on AI infrastructure. While the drop spooked some investors, management signals a near-term easing, and analysts argue the market's reaction may have overlooked the long-term payoff and underlying financial strength.
Investment firms Stifel and Northland have raised their price targets on Ondas Holdings (ONDS), following a virtual investor day where management outlined an ambitious growth roadmap, highlighting the company's unique position in military drones and private wireless networks.
A blistering rally in gold and silver reversed violently on Friday, with prices plummeting in one of the most severe single-day drops in decades, rattling markets and investors.
Diverging analyst views on Celsius Holdings highlight a pivotal moment for the high-flying energy drink stock. While some anticipate strong upcoming earnings, others point to a cooling category, aggressive discounting, and PepsiCo's inventory adjustments as signs of a more challenging road ahead, leaving investors to weigh the brand's resilience against shifting market dynamics.
Citi has updated its model for GlobalFoundries, lifting the price target to $42 and extending its valuation horizon to 2027. The move follows the chipmaker's strategic acquisition of Synopsys' ARC Processor IP business, aimed at accelerating its physical AI roadmap.
As earnings season winds down, the construction and maintenance services sector showed resilience. Great Lakes Dredge & Dock posted solid results despite a revenue miss, while peers like Primoris soared. We analyze the key drivers and what's next for these industrial players.
Shares of Advanced Drainage Systems (NYSE: WMS) have shown resilience amid recent market volatility, posting solid long-term gains. With a fair value estimate suggesting potential upside, investors are weighing the stock's premium valuation against its growth trajectory in the construction sector.
As gold prices soar past $5,400 an ounce before a sharp pullback, a global rush is underway. From Parisian boutiques to Main Street dealers, consumers are capitalizing on heirlooms or diving into the market, driven by geopolitical tensions and economic uncertainty.
The drive-thru coffee chain 7 Brew debuts a monthly rotating menu of featured beverages, starting with five options for February including a new Chocolate Dipped Strawberry Cold Brew, as it leverages its strong rewards membership to boost visit frequency.
XPO's dual recognition of driver safety excellence coincides with significant institutional options activity targeting 2026, setting the stage for a pivotal period as the company navigates leadership change and high expectations for its core LTL business.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
Franklin Templeton reported robust first-quarter results, with record long-term inflows of $118.6 billion, driven by strong demand across public and private markets. CEO Jenny Johnson highlighted the firm's strategic positioning in AI, blockchain tokenization, and integrated portfolio solutions as investors seek resilience amid ongoing market volatility.
A pivotal week in business saw Tesla's long-awaited robotaxis begin operations without safety drivers, signaling a new phase in autonomous mobility. Meanwhile, Greg Abel's early moves at Berkshire Hathaway hint at a potential strategic shift, and a push for tokenized, round-the-clock stock trading raises questions about the future of finance.
Shares of Corcept Therapeutics plunged 16% after a corrected FDA letter disclosed the agency had repeatedly cautioned the company against filing its application for a Cushing's syndrome drug, which was later rejected over efficacy and safety concerns.
Energy giant Drax has secured a decade-long tolling agreement with Fidra Energy for a new 250MW battery storage system in Nottinghamshire, marking a capital-light expansion of its flexible generation portfolio as the UK races to decarbonise.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Iran's foreign minister has unequivocally declared the nation's missile and defense capabilities non-negotiable, even as diplomatic efforts intensify to prevent a military escalation with the United States. The statement comes amid a complex backdrop of regional mediation and internal unrest.
Truist Securities raises its price target on Meta Platforms to $900, maintaining a Buy rating. The upgrade follows stronger-than-expected Q4 results and a robust Q1 outlook, driven by AI enhancements boosting ad performance and user engagement.
